ArriVent BioPharma, Inc.
AVBP
$34.00
$0.180.52%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 54.92% | 87.69% | 48.38% | 50.63% | 48.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -30.94% | 63.78% | 58.12% | 30.84% | 222.98% |
| Operating Income | 30.94% | -63.78% | -58.12% | -30.84% | -222.98% |
| Income Before Tax | 32.72% | -74.30% | -68.99% | -43.55% | -269.68% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 32.72% | -74.30% | -68.99% | -43.55% | -269.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 32.72% | -74.30% | -68.99% | -43.55% | -269.68% |
| EBIT | 30.94% | -63.78% | -58.12% | -30.84% | -222.98% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 49.39% | -36.83% | -35.39% | -37.39% | -173.14% |
| Normalized Basic EPS | 49.39% | -35.24% | -36.29% | -37.37% | -173.15% |
| EPS Diluted | 49.39% | -36.83% | -35.39% | -37.39% | -173.14% |
| Normalized Diluted EPS | 49.39% | -35.24% | -36.29% | -37.37% | -173.15% |
| Average Basic Shares Outstanding | 32.95% | 27.37% | 24.81% | 4.49% | 35.34% |
| Average Diluted Shares Outstanding | 32.95% | 27.37% | 24.81% | 4.49% | 35.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |